Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2366504 Target Snapshot

Structural capsid protein · SINGLE PROTEIN · Human immunodeficiency virus 1

Back to Search Search this target Browse approvals Evidence Card
212Compounds
61Assays
1Approved Drugs
193.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Structural capsid protein shows approved-linked disease relevance led by HIV infection. 3 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q76129. Start with HIV infection, then reuse UniProt Q76129 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with HIV infection, then reuse UniProt Q76129 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
HIV infection

Structural capsid protein shows approved-linked disease relevance led by HIV infection. 3 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with HIV infection because it currently carries approved-linked support. Linked drugs include LENACAPAVIR, LENACAPAVIR SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Structural capsid protein as ChEMBL target CHEMBL2366504, mapped to UniProt Q76129. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Structural capsid protein
SINGLE PROTEIN · Human immunodeficiency virus 1
As of 2026-09-13
ChEMBL target ID
CHEMBL2366504
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q76129
Structural capsid protein
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Structural capsid protein is the right protein anchor across sources, using UniProt Q76129 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why HIV infection is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameStructural capsid protein
Target TypeSINGLE PROTEIN
OrganismHuman immunodeficiency virus 1
UniProtQ76129
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelStructural capsid protein
UniProt AccessionQ76129
Component TypeProtein
Sequence Length115 aa

Structural capsid protein

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Structural capsid protein, mapped to UniProt Q76129. Sequence length is 115 aa.

Mapped IDQ76129
Review nameStructural capsid protein
OrganismHuman immunodeficiency virus 1
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Structural capsid protein shows approved-linked disease relevance led by HIV infection. 3 more disease programs remain visible in the same review block.

Approved-linked Approved
HIV infection
2 linked drugs · 2 direct · 2 efficacy
Linked drugLENACAPAVIR
Linked drugLENACAPAVIR SODIUM
Approved-linked Approved
HIV-1 infection
1 linked drug · 1 direct · 1 efficacy
Linked drugLENACAPAVIR SODIUM
Approved-linked Approved
viral disease
1 linked drug · 1 direct · 1 efficacy
Linked drugLENACAPAVIR
Late clinical Phase III
HIV-1 infection
1 linked drug · 1 direct · 1 efficacy
Linked drugLENACAPAVIR
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with HIV infection because it currently carries approved-linked support. Linked drugs include LENACAPAVIR, LENACAPAVIR SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseHIV infection
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase III
Assay Mix

Activity Type Distribution

IC50117.0
KI2.0
EC508.0
KD66.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4594438 10.3 EC50 0.05 Approved
CHEMBL5619085 9.7 EC50 0.2 Preclinical
CHEMBL5618694 7.92 EC50 12.0 Preclinical
CHEMBL5618074 7.72 EC50 19.0 Preclinical
CHEMBL4788393 7.58 IC50 26.6 Preclinical
CHEMBL3770825 7.42 Kd 38.0 Preclinical
CHEMBL2204010 7.42 IC50 38.0 Preclinical
CHEMBL2204005 7.39 IC50 41.0 Preclinical
CHEMBL2204007 7.36 IC50 44.0 Preclinical
CHEMBL51085 7.33 IC50 46.7 Clinical
Distribution

pChEMBL Value Distribution

30
5.0
15
5.5
19
6.0
29
6.5
19
7.0
3
7.5
0
8.0
0
8.5
0
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

LENACAPAVIR
CHEMBL4594438
Approved 2022
Properties Compare Identifier
Assay Landscape

Assay Landscape

61
Total Assays
120
Tested Compounds
1
Assay Types
Binding — 61 assays, 120 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 31 32 5.8
assay format 28 88 5.7
cell-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine